Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 2:12:875036.
doi: 10.3389/fonc.2022.875036. eCollection 2022.

Acute, Subchronic, and Chronic Complications of Radical Prostatectomy Versus Radiotherapy With Hormone Therapy in Older Adults With High-Risk Prostate Adenocarcinoma

Affiliations

Acute, Subchronic, and Chronic Complications of Radical Prostatectomy Versus Radiotherapy With Hormone Therapy in Older Adults With High-Risk Prostate Adenocarcinoma

Szu-Yuan Wu et al. Front Oncol. .

Abstract

Purpose: To compare acute, subchronic, and chronic complications between older patients with high-risk localized prostate cancer (HR-LPC) receiving radical prostatectomy (RP) and high-dose intensity-modulated radiotherapy (IMRT) combined with long-term hormone therapy (HT).

Patients and methods: We recruited older patients (≥80 years) with HR-LPC from the Taiwan Cancer Registry database. After propensity score matching, logistic regression analysis was used to compare the acute, subchronic, and chronic complication rates between patients who underwent RP (the RP group) and high-dose IMRT combined with long-term HT (the IMRT+HT group).

Results: Benign prostatic hyperplasia (BPH) symptoms and urinary incontinence (UI) were the most common complications over 5 years (BPH symptoms: RP, 17.69%; IMRT+HT, 29.58%; UI: RP, 10.47%; IMRT+HT, 5.50%). Compared with the RP group, the IMRT+HT group had higher odds of BPH symptoms and lower odds of UI and hernia after the 5-year follow-up period. The impotence rates were significantly higher in the IMRT+HT group than in the RP group at 3 months and 1 year after treatment and became nonsignificant after 2 years. At 5 years after treatment, the IMRT+HT group had lower risks of UI (adjusted odds ratio [aOR], 0.50; 95% confidence interval [CI], 0.28-0.88) and hernia (aOR, 0.21; 95% CI, 0.11-0.82) and a higher risk of BPH symptoms (aOR, 4.15; 95% CI, 2.82-7.37) than the RP group.

Conclusion: IMRT+HT was associated with lower UI and hernia risks than RP. By contrast, RP was associated with fewer complications of BPH over the follow-up period and less impotence during the first year after treatment. Our findings provide important and valuable references for shared decision-making for optimal therapy selection among older men with HR-LPC.

Keywords: complications; high-risk localized prostate cancer; intensity-modulated radiotherapy; old age; radical prostatectomy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

Cited by

References

    1. Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ. Combined Value of Validated Clinical and Genomic Risk Stratification Tools for Predicting Prostate Cancer Mortality in a High-Risk Prostatectomy Cohort. Eur Urol (2015) 67:326–33. doi: 10.1016/j.eururo.2014.05.039 - DOI - PMC - PubMed
    1. Boukovala M, Spetsieris N, Efstathiou E. Systemic Treatment of Prostate Cancer in Elderly Patients: Current Role and Safety Considerations of Androgen-Targeting Strategies. Drugs Aging (2019) 36:701–17. doi: 10.1007/s40266-019-00677-6 - DOI - PubMed
    1. Health Promotion Administration, M.O.H.a.W . Taiwan Cancer Registry Annual Report. Taipei: Health Promotion Administration; (2018).
    1. Lin P-H, Chang S-W, Tsai L-H, Kan H-C, Liu J-M, Chuang C-K, et al. . Increasing Incidence of Prostate Cancer in Taiwan: A Study of Related Factors Using a Nationwide Health and Welfare Database. Med (Baltimore) (2020) 99:e22336. doi: 10.1097/MD.0000000000022336 - DOI - PMC - PubMed
    1. Rawla PJ. Epidemiology of Prostate Cancer. World J Oncol (2019) 10:63. doi: 10.14740/wjon1191 - DOI - PMC - PubMed

LinkOut - more resources